<DOC>
	<DOCNO>NCT00436787</DOCNO>
	<brief_summary>Morbidly obese individual high risk potentially life threaten blood clot around time abdominal surgical procedure . Fondaparinux sodium ( Arixtra ) FDA- approve medication use prevention deep venous thrombosis ( DVT ) time orthopedic abdominal surgery , well treatment DVT pulmonary embolism ( PE ) . As many medication , therapeutic dosage fully investigate morbidly obese population . Our goal study therapeutic blood level , 2 different dosage medication give morbidly obese volunteer . We recruit 21 morbidly obese ( Body Mass Index ( BMI ) &gt; 35 ) individual evaluation process bariatric surgery . They divide 7 group : 3 participant BMI 35 - 39.9 , 3 BMI 40 - 49.9 , 3 BMI 50 - 59.9 , 3 BMI &gt; 60 , 3 weight 100 - 149 KG , 3 weight 150 - 199 KG 3 weight 200 - 249 KG . Participants administer two different dos medication 2-week interval , blood drawn various interval throughout next 48 hour see dose provide best therapeutic level . Participants monitor closely side effect complication .</brief_summary>
	<brief_title>Investigation Into Therapeutic Dosage Fondaparinux Sodium , Medication Used Prevent Blood Clots Morbidly Obese Volunteers</brief_title>
	<detailed_description>Bariatric surgery carry mortality rate 0.5-1 % , PE find frequent postoperative complication cause death . Currently employ prophylactic method include unfractionated low molecular weight heparin combination mechanical calf compression . However , despite implementation standard measure , report incidence fatal PE range 0.2 0.64 % accounting 30 50 % death bariatric surgery . With report 40,000 bariatric surgical procedure 2001 , number grow rapidly every year , clearly need effective prophylaxis DVT PE . The pentasaccharide fondaparinux anti-thrombotic agent use prophylaxis venous thromboembolism orthopedic abdominal surgery . Its clinical value establish multiple randomize double blind study high-risk major orthopedic surgery show 55 % great reduction DVT episode compare enoxaparin ( Lovenox® ) Although fondaparinux administer obese patient clinical study prevention venous thromboembolism orthopedic surgery preliminary result show influence ABW clinical outcome , pharmacokinetic property drug morbidly obese investigate . Previously publish fondaparinux pharmacokinetic study exclude patient whose body weight 30 % ideal , heavy group 77.2+/-10.1 Kg BMI 25.7+/2.6 Kg/m2 . Similar study low molecular weight heparin , enoxaparin dalteparin , show predictable anti-Xa activity weight-based dosing morbidly obese . There study pharmacokinetics drug morbidly obese ( BMI &gt; 35 Kg/m2 ) . It clinically imperative predictable anti-Xa level predictable DVT prophylactic effect morbidly obese whose body weight may vary much 3 4 fold high compare average 70 Kg adult . This become critical issue view large number bariatric surgical operation undertaken , increase 150 % last two year . The purpose study assess pharmacokinetic property fondaparinux morbidly obese volunteer . This prospective crossover , randomize study 2-week washout period compare two dose regimen fondaparinux morbidly obese volunteer .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>INCLUSION 1 . Age 1965 year 2 . BMI 3565 Kg/m2 3 . Pregnancy test Negative day study 4 . Past DVT/PE/MI These patient exclude provide current therapy anticoagulant , aspirin , antiplatelet agent . EXCLUSION 1 . BP ≥ 160/90 2 . Temperature &gt; 37.5 0C ( 99.5 0F ) 3 . Nursing mother Exclude nurse 4 . Pregnancy test Positive day study 5 . Medications Anticoagulants , antiplatelet agent , aspirin , NSAIDs within month study Past medical history 1. cerebrovascular accident ( include TIA within 6 month study ) 2 . Diabetic retinopathy proven fundoscopy 3 . History inherit thrombotic/hypercoagulable defect 4 . Active peptic ulcer disease diagnose upper endoscopy 5 . Known bleed disorder , thrombophilia 6 . History heparin induce thrombocytopenia 7 . History bacterial endocarditis 8 . Known hypersensitivity fondaparinux 9 . Ulcerative colitis 10 . History GI bleed 11 . History hematuria 12 . Recent surgery ( last 3 month ) 13 . Recent trauma ( last 3 month ) Laboratory value 1 . Platelet count ≤ 100,000 mm3 2 . Hemoglobin &lt; 12 g/dL ( woman ) , &lt; 14 g/dL ( men ) 3 . Prothrombin time &gt; 13 sec 4 . PTT &gt; 35 sec 5 . ALT 3xULN bilirubin 1.5xULN ( &gt; 35 % direct ) ; ALT 5xULN ; ALT 3xULN associate appearance worsen hepatitis symptom rash 6 . Estimated urinary creatinine clearance ≤ 50 ml/min 7 . Hematuria urine dipstick</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Anticoagulation Prophylaxis</keyword>
	<keyword>Venous Thrombosis</keyword>
	<keyword>Deep Vein Thrombosis</keyword>
	<keyword>Pulmonary Embolism</keyword>
	<keyword>Fondaparinux Sodium</keyword>
	<keyword>Arixtra</keyword>
	<keyword>Pharmakinetics</keyword>
</DOC>